BofA analyst Allen Lutz initiated coverage of Guardian Pharmacy (GRDN) with a Buy rating and $42 price target The firm sees “a long path of elevated growth” given Guardian’s strong track record, industry changes that are putting pressure on smaller peers and Guardian’s “best in class” purchasing and reimbursement model, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy price target raised to $43 from $38 at Truist
- Guardian Pharmacy initiated with a Buy at Jefferies
- Buy Rating on Guardian Backed by Sustainable Mid‑Teens EBITDA Growth, Market Share Gains, and Accretive Expansion Strategy
- Guardian Pharmacy Services Ends Controlled Company Status on NYSE
- Guardian Pharmacy 6M share Spot Secondary priced at $31.00